scholarly journals In vitro antibacterial activity of Psidium guajava (Guava) leaves extract on carbapenem-resistant Klebsiella pneumoniae causing multi-drug resistant systemic infections

2020 ◽  
Vol 14 (9) ◽  
pp. 475-479
Author(s):  
Kwadwo Hackman Henry ◽  
Essel Arhin Reuben ◽  
Kojo Azumah Bright ◽  
Boateng David ◽  
Nwosu Blessing ◽  
...  
2020 ◽  
Vol 10 (3) ◽  
pp. 115-124
Author(s):  
Rasmus G. Bandick ◽  
Soraya Mousavi ◽  
Stefan Bereswill ◽  
Markus M. Heimesaat

AbstractInfections with multi-drug resistant (MDR) bacteria including carbapenem-resistant Klebsiella pneumoniae are emerging worldwide but are difficult to treat with the currently available antibiotic compounds and therefore constitute serious threats to human health. This prompted us to perform a literature survey applying the MEDLINE database and Cochrane Register of Controlled Trials including clinical trials comparing different treatment regimens for infections caused by carbapenem-resistant K. pneumoniae. Our survey revealed that a combined application of antibiotic compounds such as meropenem plus vaborbactam, meropenem plus colistin and carbapenem plus carbapenem, resulted in significantly increased clinical cure and decreased mortality rates as compared to respective control treatment. However, further research on novel antibiotic compounds, but also on antibiotic-independent molecules providing synergistic or at least resistance-modifying properties needs to be undertaken in vitro as well as in large clinical trials to provide future options in the combat of emerging life-threatening infections caused by MDR bacteria.


2018 ◽  
Vol 5 ◽  
pp. 69-76
Author(s):  
Mamata Adhikari ◽  
Anil Kumar Sah ◽  
Dev Raj Joshi

Objectives: In order to investigate alternate therapeutic option, this study was carried out to assess the in vitro antibacterial activity of gel extract of Aloe barbadensis against multiple antibiotic resistant Pseudomonas aeruginosa isolated from wound specimens. Methods: A total of 180 different wound specimens collected in a hospital, were subjected to isolate and identify P. aeruginosa by cultural methods. Antibiotic susceptibility testing was done by Kirby- Bauer disc diffusion method to screen multidrug resistant isolates. A. barbadensis extracts were prepared using aqueous and organic solvents and their in vitro inhibitory action was evaluated by agar well diffusion methods. Results: Out of total, 38 (21.1%) of the wound specimens showed the occurrence of P. aeruginosa, among which 15 (39%) isolates were multi-drug resistant. Organic extracts of various concentrations (0.2 - 0.8 v/v %) inhibited 66.7% of MDR and all non-MDR (n = 23) P. aeruginosa with zone of inhibition ranging from 9.5 ±1.0 to 21.3 ± 2.2 mm but not by aqueous extract. A positive Pearson’s correlation (r=0.983) was found between antibacterial effect and concentrations of the extracts. The antibacterial activity of organic extracts was statistically associated with antibiotic resistance profile of the organism (p<0.05). Conclusion: Organic extracts of A. barbadensis revealed variable in vitro inhibitory action against both MDR and non-MDR P. aeruginosa isolated from wound specimens. Although further confirmation is needed, aloe gel extract may be applied as an alternate treatment option.


2019 ◽  
Vol 6 (Supplement_2) ◽  
pp. S314-S314
Author(s):  
Alita Miller ◽  
Sarah McLeod ◽  
Tarun Mathur ◽  
Ian Morrissey

Abstract Background The incidence of infections caused by multidrug-resistant Acinetobacter baumannii is increasing at an alarming rate in Southeast Asia and other parts of the world. Sulbactam (SUL) has intrinsic antibacterial activity against A. baumannii; however, the prevalence of β-lactamases in this species has limited its therapeutic use. Durlobactam (ETX2514, DUR) is a novel β-lactamase inhibitor with broad-spectrum activity against Ambler class A, C and D β-lactamases. DUR restores SUL in vitro activity against multidrug-resistant A. baumannii. Against >3,600 globally diverse, clinical isolates from 2012–2017, addition of 4 mg/L DUR reduced the SUL MIC90 from >32 to 2 mg/L. SUL-DUR is currently in Phase 3 clinical development for the treatment of infections caused by carbapenem-resistant Acinetobacter spp.The goal of this study was to determine the activity of SUL-DUR and comparator antibiotics (amikacin (AMK), ampicillin-sulbactam (AMP-SUL), cefoperazone-sulbactam (CFP-SUL) and meropenem (MEM)) against A. baumannii isolated from hospitalized patients in India. Methods A total of 121 clinical A. baumannii isolates from multiple hospital settings and infection sources were collected between 2016–2019 from six geographically diverse hospitals in India. Species identification was performed by MALDI-TOF. Susceptibility of these isolates to SUL-DUR (10µg/10µg) and comparator antibiotics was determined by disk diffusion using CLSI methodology and interpretive criteria, except for CFP-SUL, for which resistance was defined using breakpoints from the CFP-SUL package insert. Results As shown in Table 1, resistance of this collection of isolates to marketed agents was extremely high. In contrast, based on preliminary breakpoint criteria, only 11.5% of isolates were resistant to SUL-DUR. Conclusion The in vitro antibacterial activity of SUL-DUR was significantly more potent than comparator agents against multidrug-resistant A. baumannii isolates collected from diverse sites in India. These data support the continued development of SUL-DUR for the treatment of antibiotic-resistant infections caused by A. baumannii. Disclosures All authors: No reported disclosures.


2016 ◽  
Vol 6 (1) ◽  
Author(s):  
Abdulrahman Syedahamed Haja Hameed ◽  
Chandrasekaran Karthikeyan ◽  
Abdulazees Parveez Ahamed ◽  
Nooruddin Thajuddin ◽  
Naiyf S. Alharbi ◽  
...  

2020 ◽  
pp. FSO461 ◽  
Author(s):  
Yamuna Devi Bakthavatchalam ◽  
Abirami Shankar ◽  
Dhiviya Prabaa Muthuirulandi Sethuvel ◽  
Kalaiarasi Asokan ◽  
Kalaiarasi Kanthan ◽  
...  

Aim: To evaluate the antibacterial activity of fosfomycin–meropenem and fosfomycin–colistin combinations against carbapenem-resistant Klebsiella pneumoniae (CR-Kp). Methods: A total of 50 CR-Kp isolates recovered from blood cultures were included in this study. All the CR-Kp isolates were screened for the presence of carbapenem resistant genes blaIMP. blaVIM. blaNDM. blaOXA-48 like, blaKPC. blaGES.#x00A0;and blaSPM. Combination testing of fosfomycin–meropenem and fosfomycin–colistin were performed using time-kill assay. Results: Fosfomycin–meropenem combination showed synergy in 20% of the tested CR-Kp isolates. While, fosfomycin–colistin exhibited synergy against 16% of the isolates. A total of 68% (n = 34) of CR-Kp isolates were characterised as OXA-48-like producers and 22% (n = 11) as NDM producers. Synergistic activity of these combinations was observed against OXA-48, NDM and NDM + OXA-48 co-producers. Conclusion: Considerable synergistic antibacterial activity of fosfomycin–meropenem and fosfomycin–colistin was not observed against CR-Kp isolates. Therefore, these combinations may not be promising for infections associated with CR-Kp.


2019 ◽  
Vol 2 (4) ◽  
pp. 15
Author(s):  
Zhizhi Xie ◽  
Changzhi Xu ◽  
Yanhua Yi ◽  
Donglin Zhu ◽  
Yun Xi

Objective: To evaluate the antibacterial effects of meropenem and levofloxacin respectively combined with Galla chinensis on carbapenem-resistant Escherichia coli in vitro. Methods: The protocol was designed with checkerboard method and the carbapenem-resistant E.coli was isolated in our hospital. The minimum inhibitory concentrations(MICs) of G. chinensis alone and combined with 2 antimicrobial agents against carbapenem-resistant E.coli were determined by broth dilution method and the fractional inhibitory concentration index (FICI) was calculated according to MICs results. Result: the combined use of G. chinensis and meropenem (or levofloxacin) significantly decreased both MIC50 and MIC90; After the combination of G. chinensis and meropenem, the synergistic effect was 86.7%, and the additive effect was 13.3%, no irrelevant and antagonistic effects. After combined use of G. chinensis and levofloxacin, the synergistic effect was 66.7%, and the additive effect was 33.3%. No irrelevant and antagonistic effects. Conclusion: Galla chinensis combined with meropenem or levofloxacin has synergistic and additive antibacterial effect, with certain combined antibacterial activity.


Sign in / Sign up

Export Citation Format

Share Document